Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Advances in immunotherapy utilizing immune checkpoint inhibitors (ICIs) have transformed the treatment landscapes of several malignancies in recent years. Oncologists are now tasked with extending these benefits to a greater number of patients and tumor types. Metastatic castration-resistant prostat...

Descripción completa

Detalles Bibliográficos
Autores principales: Redman, Jason M., Steinberg, Seth M., Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145343/
https://www.ncbi.nlm.nih.gov/pubmed/30227893
http://dx.doi.org/10.1186/s40425-018-0409-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145343/
https://www.ncbi.nlm.nih.gov/pubmed/30227893
http://dx.doi.org/10.1186/s40425-018-0409-8

Ejemplares similares